These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

210 related items for PubMed ID: 12611065

  • 1. Detection of relapse by sequential monitoring of chimerism in circulating CD34+ cells.
    Thiede Ch, Lutterbeck K, Oelschlägel U, Kiehl M, Steudel Ch, Platzbecker U, Brendel C, Fauser AA, Neubauer A, Ehninger G, Bornhäuser M.
    Ann Hematol; 2002; 81 Suppl 2():S27-8. PubMed ID: 12611065
    [Abstract] [Full Text] [Related]

  • 2. Qualitative assessment of mixed chimerism after allogeneic bone marrow transplantation with regard to leukemic relapse.
    Kögler G, Hernandez A, Heyll A, Wolf HH, Wernet P.
    Cancer Detect Prev; 1996; 20(6):601-9. PubMed ID: 8939346
    [Abstract] [Full Text] [Related]

  • 3. Chimerism status is a useful predictor of relapse after allogeneic stem cell transplantation for acute leukemia.
    Barrios M, Jiménez-Velasco A, Román-Gómez J, Madrigal ME, Castillejo JA, Torres A, Heiniger A.
    Haematologica; 2003 Jul; 88(7):801-10. PubMed ID: 12857560
    [Abstract] [Full Text] [Related]

  • 4. A comparison of chimerism and minimal residual disease between four different allogeneic transplantation methods in patients with chronic myelogenous leukemia in first chronic phase.
    Elmaagacli AH, Runkel K, Steckel N, Opalka B, Trenschel R, Seeber S, Schaefer UW, Beelen DW.
    Bone Marrow Transplant; 2001 Apr; 27(8):809-15. PubMed ID: 11477437
    [Abstract] [Full Text] [Related]

  • 5. Serial and quantitative analysis of mixed hematopoietic chimerism by PCR in patients with acute leukemias allows the prediction of relapse after allogeneic BMT.
    Bader P, Beck J, Frey A, Schlegel PG, Hebarth H, Handgretinger R, Einsele H, Niemeyer C, Benda N, Faul C, Kanz L, Niethammer D, Klingebiel T.
    Bone Marrow Transplant; 1998 Mar; 21(5):487-95. PubMed ID: 9535041
    [Abstract] [Full Text] [Related]

  • 6. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease.
    Posthuma EF, Marijt EW, Barge RM, van Soest RA, Baas IO, Starrenburg CW, van Zelderen-Bhola SL, Fibbe WE, Smit WM, Willemze R, Falkenburg JH.
    Biol Blood Marrow Transplant; 2004 Mar; 10(3):204-12. PubMed ID: 14993886
    [Abstract] [Full Text] [Related]

  • 7. Monitoring of acute myeloid leukemia patients after allogeneic stem cell transplantation employing semi-automated CD34+ donor cell chimerism analysis.
    Hoffmann JC, Stabla K, Burchert A, Volkmann T, Bornhäuser M, Thiede C, Neubauer A, Brendel C.
    Ann Hematol; 2014 Feb; 93(2):279-85. PubMed ID: 24352219
    [Abstract] [Full Text] [Related]

  • 8. [Relapse of childhood ALL, AML and MDS after allogeneic stem cell transplantation can be prevented by donor lymphocyte infusion in a critical stage of increasing mixed chimerism].
    Beck JF, Klingebiel T, Kreyenberg H, Schaudt A, Wölle W, Niethammer D, Bader P.
    Klin Padiatr; 2002 Feb; 214(4):201-5. PubMed ID: 12165902
    [Abstract] [Full Text] [Related]

  • 9. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL.
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [Abstract] [Full Text] [Related]

  • 10. Need for an accurate molecular diagnosis to assess the donor origin of leukemia relapse after allogeneic stem cell transplantation.
    Spinelli O, Giussani U, Borleri G, Lazzari M, Michelato A, Dotti G, Barbui T, Rambaldi A.
    Haematologica; 2000 Nov; 85(11):1153-7. PubMed ID: 11064467
    [Abstract] [Full Text] [Related]

  • 11. Transplantation of allogeneic CD34+-selected cells followed by early T-cell add-backs: favorable results in acute and chronic myeloid leukemia.
    Kobbe G, Fenk R, Neumann F, Bernhardt A, Steidl U, Kondakci M, Graef T, Aivado M, Vaupel M, Huenerlituerkoglu AN, Kronenwett R, Pape H, Hildebrand B, Germing U, Haas R.
    Cytotherapy; 2004 Nov; 6(6):533-42. PubMed ID: 15764020
    [Abstract] [Full Text] [Related]

  • 12. Allogeneic transplantation for pediatric acute lymphoblastic leukemia: the emerging role of peritransplantation minimal residual disease/chimerism monitoring and novel chemotherapeutic, molecular, and immune approaches aimed at preventing relapse.
    Pulsipher MA, Bader P, Klingebiel T, Cooper LJ.
    Biol Blood Marrow Transplant; 2009 Jan; 15(1 Suppl):62-71. PubMed ID: 19147081
    [Abstract] [Full Text] [Related]

  • 13. Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease.
    DeAngelo DJ, Hochberg EP, Alyea EP, Longtine J, Lee S, Galinsky I, Parekkedon B, Ritz J, Antin JH, Stone RM, Soiffer RJ.
    Clin Cancer Res; 2004 Aug 01; 10(15):5065-71. PubMed ID: 15297408
    [Abstract] [Full Text] [Related]

  • 14. Early detection of relapse in patients with myelodysplastic syndrome after allo-SCT.
    Tobiasson M, Olsson R, Hellström-Lindberg E, Mattsson J.
    Bone Marrow Transplant; 2011 May 01; 46(5):719-26. PubMed ID: 20697367
    [Abstract] [Full Text] [Related]

  • 15. Quantitative analysis of chimerism after allogeneic stem cell transplantation by real-time polymerase chain reaction with single nucleotide polymorphisms, standard tandem repeats, and Y-chromosome-specific sequences.
    Koldehoff M, Steckel NK, Hlinka M, Beelen DW, Elmaagacli AH.
    Am J Hematol; 2006 Oct 01; 81(10):735-46. PubMed ID: 16838323
    [Abstract] [Full Text] [Related]

  • 16. [Allogeneic hematopoietic stem cell transplantation in patients with chronic myeloid leukemia in the Czech Republic--a retrospective analysis of results in years 1988-2005].
    Faber E, Koza V, Vítek A, Mayer J, Sedlácek P, Zák P, Zapletalová J, Benesová K, Krejcová H, Steinerová K, Maresová I, Cetkovský P.
    Vnitr Lek; 2006 Dec 01; 52(12):1172-80. PubMed ID: 17299910
    [Abstract] [Full Text] [Related]

  • 17. Mixed chimerism in the B cell lineage is a rapid and sensitive indicator of minimal residual disease in bone marrow transplant recipients with pre-B cell acute lymphoblastic leukemia.
    Zetterquist H, Mattsson J, Uzunel M, Näsman-Björk I, Svenberg P, Tammik L, Bayat G, Winiarski J, Ringdén O.
    Bone Marrow Transplant; 2000 Apr 01; 25(8):843-51. PubMed ID: 10808205
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Prognostic efficacy for measurement of real-time quantitative PCR-based major bcr/abl mRNA in patients with Philadelphia chromosome-positive leukemia].
    Takahata M, Hashino S, Fujisawa F, Kondo T, Ota S, Kobayashi S, Tanaka J, Imamura M, Asaka M.
    Rinsho Ketsueki; 2004 Dec 01; 45(12):1241-6. PubMed ID: 15678915
    [Abstract] [Full Text] [Related]

  • 20. [Application of sequential and quantitative monitoring of chimerism in allogeneic hematopoietic stem cell transplantation].
    Tang XW, Wu DP, Zhu ZL, Wang W, Sun AN, Qiu HY, Fu ZZ, Chang WR, Ruan CG.
    Zhonghua Xue Ye Xue Za Zhi; 2004 Feb 01; 25(2):78-81. PubMed ID: 14990044
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.